One pill,
once a day¹

No titration needed.¹

Three doses available. No injections.¹

Qulipta—Preventive power that has your
migraine patients covered

The recommended dose is 10 mg, 30 mg, or 60 mg orally once daily.
Concomitant Strong and Moderate CYP3A4 Inducers: Recommended dose is 30 mg or 60 mg once daily
Concomitant OATP Inhibitors: Recommended dose is 10 mg or 30 mg once daily
Severe Renal Impairment: Recommended dose is 10 mg once daily
Concomitant Strong CYP3A4 Inhibitors: Recommended dose is 10 mg once daily
End-Stage Renal Disease: Recommended dose is 10 mg once daily

Avoid use in patients with severe hepatic impairment.

DOWNLOAD DOSING CARD

see efficacy Results

Learn more

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily.
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily.
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

US-QLP-220116

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (≥5% and at least twice the rate of placebo) are nausea and constipation.

Please see full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

INDICATION

QULIPTA® (atogepant) is indicated for the preventive treatment of episodic migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: 10 mg once daily.
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily.
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS

Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

US-QLP-220116

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

The most common adverse reactions (≥5% and at least twice the rate of placebo) are nausea and constipation.

Please see full Prescribing Information.

qulipta™ dosing

One pill, once a day1

No titration needed.1

Three doses available. No injections.1

Qulipta—Preventive power that has your migraine patients covered

INDICATION

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION AND IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

INDICATION

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

qulipta^™ dosing

One pill,
once a day¹

No titration needed.¹

Three doses available. No injections.¹

Qulipta—Preventive power that has your
migraine patients covered